Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success.
Hana MullerovaJeffrey Shi Kai ChanHeath HeatleyVictoria CarterJohn TownendDerek SkinnerStefan FranzénJonathan MarshallDavid J PricePublished in: International journal of chronic obstructive pulmonary disease (2024)
The majority of patients initiating BGF experienced real-life medication success reflecting the absence of severe cardiopulmonary events. These benefits were apparent after 90-days of treatment and sustained over 180-days.
Keyphrases
- primary care
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic obstructive pulmonary disease
- prognostic factors
- adverse drug
- magnetic resonance imaging
- emergency department
- early onset
- lung function
- cross sectional
- combination therapy
- magnetic resonance
- patient reported outcomes
- air pollution
- patient reported
- general practice